Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Charcoal - Kureha

Next Previous
Drug Profile

Charcoal - Kureha

Alternative Names: AST-120; Kremezin; Kremezin Fine Granules; Kremezin IDT; MP-146; Zysa

Latest Information Update: 31 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kureha Corporation
  • Developer Conmed Pharmaceutical & Bio-Medical Corporation of Taiwan; Daiichi Sankyo Pharmaceutical (Shanghai); HK inno.N; Kureha Corporation; Mitsubishi Tanabe Pharma Corporation; Ocera Therapeutics
  • Class Absorbents; Antipruritics
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pouchitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pruritus; Renal failure
  • Discontinued Crohn's disease; Gastro-oesophageal reflux; Hepatic encephalopathy; Irritable bowel syndrome; Pouchitis

Most Recent Events

  • 31 Jul 2025 HK inno.N pipeline, July 2025 - Brandname Kremezin IDT added; THES req sent; in org table, market licensee for korea updated; dev T updated; source-3904237
  • 16 Jan 2018 Launched for Renal failure in Japan (PO, Tablet)
  • 11 Dec 2017 Ocera Therapeutics has been acquired by Mallinckrodt plc

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top